胰十二指肠切除术后硬膜外与患者自控静脉镇痛的胃肠道并发症随机临床试验
这项国际多中心随机优效性试验纳入371例择期胰十二指肠切除术患者,随机接受PCIA(n=185)或EDA(n=186),分析248例。结论认为两种镇痛方式在有效性和安全性上相当,选择不应基于胃肠道并发症的担忧,但EDA存在体重增加更多和升压药使用更多等缺点。
要点
- PCIA与EDA在胰十二指肠切除术后30天内胃肠道并发症复合终点无显著差异。
- EDA失败发生在23例(18.5%)患者中。
核心结论
- PCIA与EDA在胰十二指肠切除术后胃肠道并发症方面效果相当,选择不应基于胃肠道并发症的担忧。
- EDA与体重增加更多和升压药使用更多相关,且存在失败率。
研究设计与样本
- 自适应、实用性、国际、多中心、优效性随机临床试验,2015年6月30日至2017年10月1日进行。
- 9个欧洲胰腺外科中心,371例择期胰十二指肠切除术患者随机分配至PCIA组(n=185)或EDA组(n=186),248例(每组124例)纳入分析。
- 采用改良意向性治疗和符合方案分析,数据于2019年2月22日至4月25日分析。
主要发现
- 主要终点的单个组分、30天死亡率、术后疼痛水平及术中术后液体替代在组间均无显著差异。
- EDA失败发生在23例(18.5%)患者中。
临床怎么用
- 胰十二指肠切除术后镇痛选择PCIA或EDA均可,无需因担忧胃肠道并发症而偏好PCIA。
- 使用EDA时需注意体重增加更多和升压药使用更多的缺点,并警惕EDA失败可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Morbidity is still high in pancreatic surgery, driven mainly by gastrointestinal complications such as pancreatic fistula. Perioperative thoracic epidural analgesia (EDA) and patient-controlled intravenous analgesia (PCIA) are frequently used for pain control after pancreatic surgery. Evidence from a post hoc analysis suggests that PCIA is associated with fewer gastrointestinal complications. OBJECTIVE: To determine whether postoperative PCIA decreases the occurrence of gastrointestinal complications after pancreatic surgery compared with EDA. DESIGN, SETTING, AND PARTICIPANTS: In this adaptive, pragmatic, international, multicenter, superiority randomized clinical trial conducted from June 30, 2015, to October 1, 2017, 371 patients at 9 European pancreatic surgery centers who were scheduled for elective pancreatoduodenectomy were randomized to receive PCIA (n = 185) or EDA (n = 186); 248 patients (124 in each group) were analyzed. Data were analyzed from February 22 to April 25, 2019, using modified intention to treat and per protocol. INTERVENTIONS: Patients in the PCIA group received general anesthesia and postoperative PCIA with intravenous opioids with the help of a patient-controlled analgesia device. In the EDA group, patients received general anesthesia and intraoperative and postoperative EDA. MAIN OUTCOMES AND MEASURES: The primary end point was a composite of pancreatic fistula, bile leakage, delayed gastric emptying, gastrointestinal bleeding, or postoperative ileus within 30 days after surgery. Secondary end points included 30-day mortality, other complications, postoperative pain levels, intraoperative or postoperative use of vasopressor therapy, and fluid substitution. RESULTS: Among the 248 patients analyzed (147 men; mean [SD] age, 64.9 [10.7] years), the primary composite end point did not differ between the PCIA group (61 [49.2%]) and EDA group (57 [46.0%]) (odds ratio, 1.17; 95% CI, 0.71-1.95 P = .54). Neither individual components of the primary end point nor 30-day mortality, postoperative pain levels, or intraoperative and postoperative substitution of fluids differed significantly between groups. Patients receiving EDA gained more weight by postoperative day 4 than patients receiving PCIA (mean [SD], 4.6 [3.8] vs 3.4 [3.6] kg; P = .03) and received more vasopressors (46 [37.1%] vs 31 [25.0%]; P = .04). Failure of EDA occurred in 23 patients (18.5%). CONCLUSIONS AND RELEVANCE: This study found that the choice between PCIA and EDA for pain control after pancreatic surgery should not be based on concerns regarding gastrointestinal complications because the 2 procedures are comparable with regard to effectiveness and safety. However, EDA was associated with several shortcomings. TRIAL REGISTRATION: German Clinical Trials Register: DRKS00007784.
引用
- Klotz R, Larmann J, Klose C, et al. Gastrointestinal Complications After Pancreatoduodenectomy With Epidural vs Patient-Controlled Intravenous Analgesia: A Randomized Clinical Trial. JAMA Surg. 2020. PMID: 32459322. doi:10.1001/jamasurg.2020.0794
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。